Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data ...

Eyeing the success of GLP-1s are Chinese biopharmaceutical companies pushing semaglutide biosimilars and GLP-1 therapy candidates up the pipeline. And the crowding market is pushing the innovators to ...

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss ...

But as of Q2, it has approximately $1.4 billion in cash, cash equivalents, and marketable investments on hand, and a pipeline that's chock-full of clinical-stage candidates that use GLP-1 and ...

Therefore, based on existing growth, the company appears fully valued, but without a major premium for the GLP-1 pipeline potential. Pharmacokinetics is the science related to the bodily processes ...

Despite competition in the field, Structure's progress and diverse pipeline of candidates make it a potentially strong investment opportunity. Glucagon-like peptide-1, or "GLP-1", agonist drugs ...

These GLP-1 agonists, which were initially prescribed ... and substantial investments in manufacturing and its pipeline, have led some investors to consider the reality that this top biotech ...

The global GLP-1 receptor agonist market size is expanding at a CAGR of 21.65% from 2024 to 2030" Continued: "The strong product pipeline and formulation advancements are driving the market.